 |
| Howard S. Jonas |
Chairman of the Board
|
|
|
Howard S. Jonas has served as Chairman of the Board of Directors of the Company since August 17, 2017
and served as Chief Executive Officer from March 8, 2018 through April 30,
2021. Mr. Jonas has been a director of Rafael Pharmaceuticals since
April 2013 and was appointed Chairman of the Board in April 2016.
Mr. Jonas founded IDT in August 1990, and has served as Chairman of
its Board of Directors since its inception. Mr. Jonas served as Chief
Executive Officer of IDT from October 2009 through December 2013.
Mr. Jonas has served as Chairman of the Board of Directors of Genie Energy
Ltd. since January 2011, when it was spun off from IDT, and served as
Chief Executive Officer of Genie from January 2014 until
November 2017. Mr. Jonas served as the Chairman of the Board of
Zedge, Inc., a former subsidiary of IDT that was spun off to stockholders in
June 2016, from June 2016 to November 2016, and as the Vice
Chairman of Zedge since November 2016. Mr. Jonas also serves as
Chairman of the Board of IDW Media Holdings, Inc., a former subsidiary of IDT
that was spun off to stockholders in September 2009 and served as Chief
Executive Officer until April 2020. Mr. Jonas is also the founder and
has been President of Jonas Media Group (f/k/a Jonas Publishing) since its
inception in 1979. Mr. Jonas received a B.A. in Economics from Harvard
University.
|
|
 |
| William 'Bill' Conkling |
Chief Executive Officer
|
|
|
| William Conkling has served as the Chief Executive Officer since February 2022 and served as the Chief Commercial and Business Officer of the Company from March 8, 2021 to January 31, 2022. Mr. Conkling has over 20 years’ experience in the pharmaceutical/biotech industry working in Oncology. He has extensive experience launching innovative oncology products. His experience has spans across all areas of commercialization including marketing, sales, market access, commercial operations and business development. Prior to joining the Company, Mr. Conkling helped lead the launch of Trodelvy at Immunomedics Inc. (acquired by Gilead for $21B in October 2020) as the VP Sales, Marketing and Market Access. Mr. Conkling also spent over 10 years at Novartis Oncology where he helped lead the launch of the first CAR-T therapy approved in the US as the Global Commercial Leader — Kymriah. Mr. Conkling earned his Bachelor’s Degree from Fordham University and his Master’s in Business Administration from New York University Stern School of Business in 1998.
|
|
 |
| Patrick Fabbio |
President and Chief Financial Officer
|
|
|
| Patrick Fabbio has served as President since November 2021 and Chief Financial Officer of the Company since September 2021. Mr. Fabbio has more than 25 years of financial, operational and transactional leadership experience in both publicly traded and privately held life science and pharmaceutical companies. Prior to joining Rafael Holdings, Mr. Fabbio was Chief Financial Officer of WindMIL Therapeutics Inc. Previously he served as the Chief Financial Officer of Progenics Pharmaceuticals, Inc., electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. Mr. Fabbio is a board member of BeyondSpring Therapeutics, Inc..
|
|
